However, although the present data suggest that targeting Pin1 in CD44+CD133+ colorectal tumor-initiating cells is a promising therapeutic approach, there are some limitations regarding the use of Pin1 inhibitors for treating human disease. Here, CD44 is linked to colorectal neoplasm.